30 closest matches · ranked by relevance
Relapsed or Refractory EBV-and CD30-positive Lymphomas
Primary: To Evaluate the Overall Response Rate (ORR) of Brentuximab Vedotin in EBV- and CD30-positive Lymphomas — 12 Participants
EBV-induced Lymphomas · EBV-associated Malignancies · Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma
Primary: Objective Response Rate (ORR) — 68.0; 50.0; 16.0; 14.3 Percentage of participants
Hodgkin Disease · Non Hodgkin Lymphoma · Lymphoepithelioma
Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…
Epstein-Barr Virus-Associated Lymphoma · Lymphoproliferative Disorders
Primary: Number (Proportion) of Participants With Adverse Events (AEs) — 7; 5; 4; 4 Participants
EBV-induced Lymphomas · EBV-associated Malignancies · Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
Primary: Objective Response Rate (ORR) — 63.6; 50.0; 0; 43.5 Percentage of participants
Post-transplant Lymphoproliferative Disease · Solid Organ Transplant · Stem Cell Transplant (Bone Marrow Transplant)
Primary: Overall Response Rate — 3 Participants
Hodgkin's Disease · Leukemia · Myelodysplastic Syndrome
Primary: Safety of Rituximab Prophylaxis — 23 participants
EBV-Related Post-Transplant Lymphoproliferative Disorder · Monomorphic Post-Transplant Lymphoproliferative Disorder · Polymorphic Post-Transplant Lymphoproliferative Disorder
Primary: Percentage of Patients Assigned to Arm Latent Membrane Protein-specific T-cells (LMP-TC) With Successful LMP-specific T Cell Product Match, Were Treated Within Two Weeks…
Lymphoma, AIDS-related · Lymphoma, Large B-Cell, Diffuse
Primary: Median Progression Free Survival (PFS) — 13.8 years
Nasopharyngeal Carcinoma
Primary: Best Overall Response Rate (ORR) — 0.0 percentage of participants
Burkitt Lymphoma · Diffuse Large B-cell Lymphoma, c-MYC Positive · Plasmablastic Lymphoma
Primary: Percentage of Participants With Kaplan-Meier Curve Progression Free Survival (PFS) Constructed With an 95% Confidence Interval — 100; 82.1; 71.0 percentage of participants
Leukemia-Lymphoma, Adult T-Cell
Primary: Tolerability of Treatment as Measured by Number of Participants With Grade 3 or Higher Adverse Events — 1; 1; 1; 2 participants
Lymphoma
Primary: Overall Survival (OS) at 1 Year — 1.0; 0.82 Cumulative proportion surviving at 1 yr
Lymphoproliferative Disorder
Primary: Event-free Survival — 71 percentage of participants analyzed
Diffuse Large B-Cell Lymphoma (DLBCL) · Primary Mediastinal Large B-cell Lymphoma · Burkitt Lymphoma
Primary: Overall Response (Complete Response + Partial Response) — 216; 94 Participants
T-Cell Lymphoma · B-Cell Lymphoma
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…
Lymphoma, T-Cell · Lymphoma, Extranodal NK-T-Cell
Primary: Maximum Tolerated Dose (MTD) of Alemtuzumab — 30 mg
B-Cell Lymphoma
Primary: Clinical Response Rate — 1; 7; 0; 8 Participants
Diffuse Large B Cell Lymphoma Relapsed · Diffuse Large B Cell Lymphoma Refractory
Primary: Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability — 0; 0; 0; 1 Participants
AIDS-Related Burkitt Lymphoma · Atypical Burkitt/Burkitt-Like Lymphoma · High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Primary: Participants With a Response — 9 Participants
AIDS-related Diffuse Large Cell Lymphoma · AIDS-related Diffuse Mixed Cell Lymphoma · AIDS-related Diffuse Small Cleaved Cell Lymphoma
Primary: Overall Survival — 0; 0 Proportion of participants
AIDS-Related-Primary Central Nervous System Lymphoma
Primary: Number of Patients Alive at 2 Years Without Recurrent Brain Lymphoma or Severe Neurocognitive Defects — 8 Participants
T-Cell Peripheral Lymphoma · Gamma Delta Hepatosplenic T-Cell Lymphoma · Subcutaneous Panniculitis-Like T-Cell Lymphoma
Primary: Number of Participants With Serious and Non-serious Adverse Events — 3; 3; 3; 5 Participants
Adult Grade III Lymphomatoid Granulomatosis · B-cell Chronic Lymphocytic Leukemia · Contiguous Stage II Adult Diffuse Large Cell Lymphoma
Primary: Dose-limiting Toxicity (Phase I) — 0; 0; 2 Participants
Non-Hodgkin Lymphoma · Mycosis Fungoides
Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects
Effect of Drugs
Primary: Objective Response Rate (ORR) Before First PD — 60.7 Percentage of Participants
AIDS-Related Hodgkin Lymphoma · Ann Arbor Stage II Hodgkin Lymphoma · Ann Arbor Stage IIA Hodgkin Lymphoma
Primary: Maximal Tolerated Dose of Brentuximab Vedotin (Phase I) — 1.2 mg/kg
AIDS-related Diffuse Large Cell Lymphoma · AIDS-related Immunoblastic Large Cell Lymphoma · AIDS-related Peripheral/Systemic Lymphoma
Primary: Complete Response Proportion as Measured by Tumor Response After Completion of Study Treatment — 0.69; 0.53 proportion
Hodgkin Lymphoma · Diffuse Large B-Cell Lymphoma
Primary: Progression Free Survival (PFS) — 6.6 months
Lymphoma, Non-Hodgkin · Lymphoma · Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell
Primary: Overall ObjectiveResponse (ORR) Rate — 0; 7; 19; 4 participants